Market Access Strategy

The way you approach your chosen market is key when it comes to launching a drug in the rare diseases sector. For biotech and pharmaceutical businesses committed to making a difference in this landscape, a robust market access strategy serves as a cornerstone for successful drug launches and sustainable commercialisation efforts.

How we work

Our network of clinical experts, combined with our local market insights, on the ground personnel and strong data-led insights, combines to offer the strongest possible opportunity for market optimisation for your drug. Success depends on a deep understanding of the intricacies inherent in the rare disease market, combined with a local market access knowledge that can pinpoint opportunities as they arrive and navigate regulations and tender processes with experience.

Unlike more prevalent conditions, rare diseases pose distinctive hurdles, including limited patient populations, complex diagnosis pathways, and fragmented healthcare infrastructures. It’s important to adopt a targeted approach that considers the unique dynamics of each rare disease ecosystem. Our complete, end-to-end commercialisation solution fosters transparency, trust, and collaboration across the network, driving the most effective decisions and leading to a successful drug launch.

Focusing on knowledge

Our aim is always to get your drug into the patient’s hands in the most timely way possible. To do so, we engage with key medical stakeholders in our relevant territories, working with KOLs in the market, facilitating advisory boards and driving medical strategy to be sure that the drug and its benefits are recognised by as many of the relevant prescribing authorities as possible. Effective communication and education play a pivotal role in market access strategy execution, backed by our excellent in-market teams.

At the same time, our team of data analysts work across the pricing landscape, identifying the correct balance between affordability and sustainability, while considering the high development costs associated with orphan drugs, and the limited patient pool. We conduct regular detailed health economic analyses to ensure favourable reimbursement outcomes, making it possible for you to price your product effectively to reflect its in market value.

Sustaining success through the lifecycle

While much of our market access activity is focused on preparing your drug for market in the most detailed way possible, we also continue to work post-launch, using data collection, market support and HEOR to generate compelling evidence that builds a case for further market adoption.

We continually monitor market dynamics, patient outcomes, and reimbursement landscapes to adapt market access tactics and pricing strategies for the best possible outcome. This allows us to be responsive and agile across the lifecycle of the drug, maximising its impact and ensuring sustained market penetration over time. Effective market access strategies not only drive commercial success but also contribute to meaningful advancements in the treatment landscape for rare diseases.